

Subject Index

Addison's disease, memory impairment in, 209

Adrenal steroids

and brain morphology, 10

and dentate gyrus formation, 77

cell birth effects of, 80-81

cell migration effects of, 82

cell survival effects of, 78-80

direct *versus* indirect effects of, 82-83

Aging. *See also* Alzheimer's disease

cognitive decline in, 184-186

cholinergic systems and, 166-168

and memory, 214

and neurodegenerative diseases, 184

NGF/NGF-receptors and, 173

vasopressin expression during, 106-107

Alzheimer's disease. *See also* Aging

cholinergic neuron loss and, 166

estradiol-enhanced memory in, 29

estrogen and, 184, 186, 226

in post-menopausal women, 12

ERT and, 227, 233-236

sex differences in, 12

Androgens

in motoneuron repair, 141-143, 155-156

gender differences in, 153-155

and vasopressin production, 102-105

Apoptosis, glucocorticoids and, 247-248

Avian neurobiology

integration, 31-32

neurogenesis, 30-31

Avian song production

adult plasticity in, 28-30

anatomical shifts in, 29-30

day-length cues in, 29

song system neuroanatomy changes and, 28-29

Avian song system

auditory song learning, 23

endocrine interactions during, 26

rate of, 25

selective neuron activation during, 25

structural changes during, 24

day length and, 29

earliest development, 21-23

HVC in, 20-26, 28-32

learning and, 19-21

motor song learning

in adulthood, 27-28

anatomical sex difference changes and, 26

gonadal steroids role in, 27

in plastic phase, 26-27

neuroendocrine interactions and, 19-21

neuron types in, 21

seasonal changes in, 28-29

sexual dimorphism in, 21

Basal forebrain

cholinergic systems in, 167

estrogen and, 174-183

and cognition, 167

ERT effects in, 165, 184

Brain. *See also* Basal forebrain;

Hippocampus; Hypothalamus

hormone-induced changes in, 45

non-genomic steroid hormone action in, 5

reversible changes in, 45-46

steroid hormone action in, 4-5

vasopressin innervation of, 96-99

sexual dimorphism in, 95-99

steroid-responsivity of, 99-113

Brain structure

hormonal effects on, 9-10

sex differences in, 6

developmental determinants of, 6-9

CAH. *See* Congenital adrenal hyperplasia

Catamenial epilepsy

cyclical nature of, 11

sex hormone levels and, 11-12

ChAT activity

cholinergic neuron impairment and, 167

and cognition, 166-167

ERT effects on, 175-178

estrogen effects on, 174-175

ChAT levels

ERT and, 175-178

estrogen and, 174-175

Cholinergic neurons

and cognitive processes, 167-168

loss of

in age-related cognitive decline, 167

and Alzheimer's disease, 166

NGF-responsive, 165

Cholinergic systems

and cognition

aging and, 166-168

learning/memory functions, 166

ERT and, 165-166

and NGF receptor expression, 179-182

Cognition

age-related decline in, 166-168

ChAT activity and, 166-167

cholinergic neuron impairment and, 167

cholinergic systems and, 166

- ERT and, 183-186
- in neurodegenerative disease, ERT and, 184
- NGF and, 173
- sex differences in, 214-216
- Congenital adrenal hyperplasia (CAH), 215
- Cushing's syndrome, memory impairment in, 209

Dementia

- ERT for, 12
- estrogen reduction of, 1
- Dendritic spine density
 - estrogens and, 52-53
 - fluctuations in, 51-52
 - gonadal steroids and, 46-51
 - and lordosis, 52, 54-55
 - sex differences in, 9
 - testosterone and, 54-55
- Dentate gyrus
 - adrenal steroids and, 77-78
 - and cell birth, 80-81
 - and cell migration, 82
 - and cell survival, 78-80
 - direct *versus* indirect effects, 82-83
 - cell birth-cell death relationship in, 86-88
 - development of
 - adrenal steroids-excitatory input interactions in, 85-86
 - excitatory amino acids and, 83-85
 - formation of, 74
 - in adulthood, 76-77
 - in embryonic period, 74-75
 - in postnatal period, 75-76
- Diethylstilbestrol (DES), women exposed to
 - cognitive functions in, 215-216
 - learning disabilities in, 215-216
- Dyscalculia, 215
- Dyslexia, 215

Epilepsy.

- See also* Catamenial epilepsy
- estrogen effect on, 1
- ERT. *See* Estrogen replacement therapy
- Estradiol. *See also* Estrogen
 - double role of, 6
 - and HVC, 23
 - spatial memory enhancement by, 207-208
 - synapse induction by, 7-8
- Estrogen. *See also* Estradiol; Gonadal hormones; Sex hormones; Testosterone
 - and cholinergic systems, 174-183
 - and cognitive function, 183-184, 226

- and dementia, 1, 12
- and dendritic spine density, 52-53
- effects of
 - on ChAT activity, 174-175
 - on cognitive function, 184-185
 - hypothetical mechanism of, 182-183
 - on memory, 213-227
 - on NGF cholinergic function, 185
 - on NGF receptors, 175-179
- and epilepsy, 1, 11-12
- and female reproductive system aging, 66-69
- and hypothalamus development, 61-62
- and lordosis, 49, 51, 54-55
- and mood, 224-225
- morphological alterations induced by, 46
- and Parkinson's disease, 1
- and post-menopausal dementia, 1
- and post-synaptic membrane organization, 62-65
- and synaptic plasticity, 52, 65-66
- synaptogenesis regulation by, 61-69
- and vasopressin production, 102-105
- Estrogen deficiency
 - and Alzheimer's disease, 226-227, 233-236
 - and osteoporosis, 226
- Estrogen replacement therapy (ERT)
 - and age-related cognitive deficits, 184
 - for Alzheimer's disease, 227, 233-236
 - and basal forebrain cholinergic function, 184
 - and ChAT activity, 175-178
 - and ChAT levels, 178-179, 183-184
 - and cholinergic systems, 165-166, 174-175
 - and cognitive function, 184
 - for dementia, 1, 12
 - and memory, 183-185, 226-227
 - and neurodegenerative disease, 184-185
 - and NGF receptor levels, 178-179, 184
 - in post-menopausal women, 218-223

Gender differences.

- See* Sex differences
- Gene expression, hormonal control of, 5
- Glucocorticoids
 - and apoptosis, 247-248
 - as immunosuppressive agents, 247
- Glucocorticoid therapy
 - anti-inflammatory mechanism of, 245-247
 - doses used, 242-243
 - in neuroprotection, 247-248
 - pulsed, 244-245
 - in spinal cord injury, 241-242
 - time window for, 243-244

- Gonadal hormones. *See also* Estrogen; Sex hormones; Steroid hormones; Testosterone
 activational effects of, 45-46
 and brain damage, 12
 and brain development, 45
 and brain morphology, 9-10
 and dendritic spine density, 46-51
 effects of, 95-96
 cellular basis of, 102-105
 on neurotransmitter activity, 95-96
 on nonreproductive behaviors, 165
 sex differences in, 96-99
 on vasopressin systems, 107-109
 in motoneuron regeneration, 143-156
 gender differences in, 153-155
 and neuronal plasticity, 45-55
 as neurotrophic agents, 141-143
 and sex differences, 1-3, 45
 and vasopressin pathways, 101-102
 Gonadal steroids. *See* Gonadal hormones

- Highest vocal center (HVC)
 in avian song system, 20-21
 cell death effects in, 22
 cell death rates in, 22
 changes during song learning period, 24
 and conspecific song discrimination, 30
 early development of, 21-22
 endocrine neurons in, 21
 estradiol and, 23
 in males, 24-25
 projections to/from, 20, 22
 seasonal changes in, 28-29
 sexual dimorphism in, 21-22
 in song system development, 21-22

- Hippocampus. *See also* Brain restructuring in, 201-203
 steroid hormone levels and, 202
 sex differences in, 10-11

- Hormone action
 and gene expression, 4-5
 mechanism of, 4-5
 non-genomic, 5

- Hormone effects, on morphology, 9-10

- Hormone levels
 sex differences in, 4
 in young adult humans, 2

- Hormone metabolism, sex differences in, 3-4

- Hypothalamus. *See also* Brain
 dendritic spine density in
 estrus and, 49-51
 gonadal steroids and, 46-49
 and lordosis behavior, 49, 51
 ultrastructural observations, 51-53

- neuronal plasticity in
 estrogen and, 46
 gonadal steroids and, 45-46

- I
 Ischemia
 degeneration/restructuring following,
 129-135
 mossy fiber system and, 122-129
 and neuronal death, 121
 selective vulnerability and, 121-122

- L
 Late luteal phase dysphoric disorder
 (LLPDD), sex hormone levels and,
 12

- Learning
 aging and, 166-168
 ChAT activity and, 166-167, 173
 cholinergic neuron impairment and, 167
 cholinergic systems and, 166
 estrogen and, 183-185
 NGF and, 173

- Learning disabilities. *See also* Dyscalculia;
 Dyslexia
 in CAH, 215
 in DES-exposed women, 215-216
 sex differences in, 12

- LLPDD. *See* Late luteal phase dysphoric disorder

- Long-term memory (LTM), 213-214

- Lordosis
 dendritic spine density fluctuations and,
 49-51
 dendritic spine induction and, 52, 54-55
 estrogen and, 49, 51, 54-55
 estrogen-induced, 185
 serotonin control in, 54
 testosterone and, 54-55
 Lordosis behavior, 49, 51
 LTM. *See* Long-term memory

- M
 Memory. *See also* Long-term memory;
 Short-term memory
 aging and, 166-168, 214, 226
 Alzheimer's disease and, 226
 estradiol effects in, 209
 ChAT activity and, 166-167, 173
 cholinergic neuron impairment and, 167
 cholinergic systems and, 166
 component processes of, 213-214
 ERT and, 183-185, 226-227
 estradiol-enhancement of, 209

- impairment of
 - in Addison's disease, 209
 - in Cushing's syndrome, 209
- neuron population stability and, 73
- in women
 - estrogen maintenance of, 226
 - menstrual cycle studies of, 217
- Mental disorders, sex differences in, 12
- Mossy fibers system, and ischemic cell death, 122-123
 - mechanism of, 128-129
 - spiny interneurons in, 123-128
- Motor neuron repair
 - androgens in, 143-144, 155-156
 - central neural plasticity alterations, 155-156
 - gender differences in, 153-155
 - gonadal steroids and, 141-143
 - testosterone effects on, 143-153

- N**erve growth factor (NGF). *See also* Cholinergic systems; Neuropeptides
- and aging, 173
 - cholinergic function of
 - in cognition, 173
 - estrogen effects on, 185
 - Nerve growth factor (NGF) receptors
 - in adult brain, 169-172
 - and basal forebrain cholinergic neurons, 168-169
 - cholinergic regulation of, 179-182
 - ERT and, 175-179
 - and NGF effects, 172-173
 - Neurodegenerative diseases, estrogen and, 184-185
 - Neurogenesis, 30-31
 - adrenal steroids and, 78-83
 - in avian neurobiology, 30-31
 - in dentate gyrus formation, 73-74
 - in adulthood, 76-77
 - in embryonic period, 74-75
 - in postnatal period, 75-76
 - in mammalian systems, 73
 - Neuronal death. *See also* Ischemia
 - degeneration/restructuring following, 129-135
 - mossy fiber system and, 122-129
 - selective vulnerability and, 121-122
 - Neuronal regeneration, 45
 - Neurons. *See also* Cholinergic neurons
 - Neuropeptides. *See also* Nerve growth factor; Neurotransmission; Vasopressin
 - as gatekeepers, 95-96
 - steroid effects on, 95-96

- Neurotransmission
 - gonadal steroid effects on, 95-96, 106
 - vasopressin expression and, 106

- O**steoporosis, as estrogenic effects model, 226, 234

- P**arkinson's disease
 - estrogen-exacerbated symptoms in, 12
 - estrogens and, 1
- Phenotypic sex characteristics, reversal of, 2-3
- Premenstrual tension. *See* Late luteal phase dysphoric disorder
- p75^{NGFR}. *See* Nerve growth factor receptors

- R**egeneration
 - of motoneurons
 - androgens and, 141-143, 155-156
 - testosterone and, 143-153
 - of peripheral nerves
 - gender differences in, 153-155
 - molecular mechanism underlying, 150-153
- Ru486, and synapse elimination blockage, 10

- S**chizophrenia, 12
- Serotonin, and lordosis control, 54
- Sex differences
 - in Alzheimer's disease, 12
 - in avian song system, 21
 - in brain structure, 6
 - in cognitive functioning, 214-216
 - in dendritic spine synapse density, 9
 - determinants of, 2-3
 - in vertebrates, 3
 - developmental determinants of
 - estradiol, 6-7
 - neonatal sex steroids, 6, 8
 - testosterone, 6-9
 - in disease occurrence, 12-13
 - in gonadal hormone effects, 96-99
 - gonadal hormones and, 1-3, 45
 - hippocampus and, 10-11, 13
 - hormonally determined variations in, 3
 - in hormone levels, 4
 - in hormone metabolism, 4-5
 - in learning disabilities frequency, 12

- in peripheral nerve regeneration, 153-155
in psychotropic drug actions, 12-13
in response to sex hormones, 6-9
reversal of, 2-3, 6
in schizophrenia frequency, 12
in serotonergic/dopaminergic function, 11
in stress-related neuronal loss, 12
testosterone metabolism and, 3-4
in vasopressin cell development, 104-105
in vasopressin expression, 100-101
in vasopressin innervation, 96-99
- Sex hormones. *See also* Estrogen; Gonadal hormones; Testosterone
and LLPDD, 12
and morphological changes
 cyclical, 9-10
 in hippocampus, 10-11
 in serotonergic/dopaminergic function, 11
and neural tissue, 1
and neuropeptide gene expression, 5
non-genomic actions of, 5
roles of, 1
- Sexual dimorphism. *See* Sex differences
- Short-term memory (STM), 213-214
- Spatial memory
adrenalectomy and, 206-207
estradiol-enhancement of, 207-208
 clinical implications of, 208-209
stress-induced impairment of, 204-205
testing of, 203-204
- Steroid hormone activation effects
on cognitive functioning, 217-218
menstrual cycle and, 216-218
on spatial functioning, 216
- Steroid hormones. *See also* Gonadal hormones
and hippocampus restructuring, 201-203
STM. *See* Short-term memory
- Stress
and hippocampal neuronal loss, 12
and spatial memory impairment, 204-206
- Synaptic plasticity, during ovarian cycle, 65-66
- Synaptogenesis
estradiol and, 10
estrogen regulation of, 61-69
- T**estosterone
and dendritic spine density, 54-55
and lordosis, 54-55
and phenotypic sex characteristics reversal, 2-3
and sex differences, 2-3, 6-9
and vasopressin expression, 100-101
and vasopressin production, 102-105
- Testosterone effects
on cranial motoneuron recovery, 146-148
on facial paralysis recovery, 144-146
on peripheral nerve regeneration
 gender differences in, 153-155
 molecular mechanism underlying, 150-153
on spinal motoneuron regeneration, 149-150
- Testosterone metabolism, and sex differences, 3-4
- TrkA. *See* Nerve growth factor receptors
- V**asopressin. *See also* Neuropeptides
as "gatekeeper," 95-96
- Vasopressin cell development, sex differences in, 104-105
- Vasopressin expression
hormone effects on, 99-102
 in adulthood, 99-102
 during aging, 106-107
 cellular basis of, 102-105
 functional significance of, 107-109
 and neurotransmission, 106
 sex differences in, 100-101
sex hormones and, 102-105
steroid-responsive
 coordination of functions in, 109-112
 in humans, 112-113
- Vasopressin innervation
of brain, 96-97
 sexual dimorphism in, 96-99
steroid-responsivity of, 99-100
 coordination of functions, 109-112
 in humans, 112-113
- Vasopressin projections. *See* Vasopressin innervation
- W**omen
Alzheimer's disease in, 12, 227, 233-236
- DES-exposed
cognitive functions in, 215-216
learning disabilities in, 215-216
memory in, estrogenic effects on, 213
post-menopausal
 dementia in, 1
 estradiol-enhanced memory in, 209
 hormone replacement therapy in, 218-223
stress-related disorders and, 12



Index of Contributors^a

Al-Shamma, H. A., 95-120

Buzsáki, G., 121-140

Constantini, S., 241-265

De Vries, G. J., 95-120
DeVoogd, T. J., 19-43

Fillit, H., 233-239
Frankfurt, M., 45-60

Gallyas, F., 121-140
Garcia-Segura, L. M., 61-71
Gibbs, R., 17, 42, 60, 92, 93, 163,
165-199, 230, 238
Gould, E., 73-93
Grayson, M., 17

Harding, C., 42-43, 265
Harvey, M., 17, 42, 140, 265
Horváth, Z., 121-140
Hsu, M., 121-140

Jones, K. J., 141-164, 197, 199

Kume-Kick, J., 241-265

Leedom, L., 61-71
Lewis, C., 61-71
Luine, V. N., 60, 93, 140, 162, 198,
201-211, 231

Masakowski, Y., 231
McEwen, B. S., 1-18
Messer, A., 164
Moller, P., 59
Moorjani, B., 17-18, 41, 60, 92, 163,
197, 198, 263, 264

Naftolin, F., 59, 61-71

Panteon, R., 161, 163

Schwartz-Giblin, S., 42, 59, 140
Sherwin, B. B., 213-231, 238
Shupack, C., 140
Sik, A., 121-140
Sterbank, L., 239

Thompson, R., 43

Voustianouk, A., 41, 139

Young, W., 241-265

Zeigler, P., 162
Zhou, L., 95-120

^a Page numbers shown in italics refer to comments made in discussions.